HER2: defining a Neu target in non-small-cell lung cancer

被引：16

作者：

Ekman, S. ^{[1
]}

机构：

[1] Karolinska Inst, Karolinska Univ Hosp, Thorac Oncol Ctr, Dept Oncol Pathol, Stockholm, Sweden

来源：

ANNALS OF ONCOLOGY | 2019年 / 30卷 / 03期

关键词：

PHASE-II TRIAL; TRASTUZUMAB; MUTATION; GENE; AMPLIFICATION; SURVIVAL; THERAPY; TUMORS;

D O I：

10.1093/annonc/mdz043

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：353 / 355

页数：3

共 27 条

[1] Phase II study of afatinib, an irreversible ErbB family blocker, in demographically and genotypically defined lung adenocarcinoma [J].

De Greve, Jacques ;

Moran, Teresa ;

Graas, Marie-Pascale ;

Galdermans, Daniella ;

Vuylsteke, Peter ;

Canon, Jean-Luc ;

Schallier, Denis ;

Decoster, Lore ;

Teugels, Erik ;

Massey, Dan ;

Chand, Vikram K. ;

Vansteenkiste, Johan .

LUNG CANCER, 2015, 88 (01) :63-69

[2] EGFR mutation correlates with uninflamed phenotype and weak immunogenicity, causing impaired response to PD-1 blockade in non-small cell lung cancer [J].

Dong, Zhong-Yi ;

Zhang, Jia-Tao ;

Liu, Si-Yang ;

Su, Jian ;

Zhang, Chao ;

Xie, Zhi ;

Zhou, Qing ;

Tu, Hai-Yan ;

Xu, Chong-Rui ;

Yan, Li-Xu ;

Li, Yu-Fa ;

Zhong, Wen-Zhao ;

Wu, Yi-Long .

ONCOIMMUNOLOGY, 2017, 6 (11)

[3] HER2-targeted therapy reduces incidence and progression of midlife mammary tumors in female murine mammary tumor virus huHER2-transgenic mice [J].

Finkle, D ;

Quan, ZR ;

Asghari, V ;

Kloss, J ;

Ghaboosi, N ;

Mai, E ;

Wong, WL ;

Hollingshead, P ;

Schwall, R ;

Koeppen, H ;

Erickson, S .

CLINICAL CANCER RESEARCH, 2004, 10 (07) :2499-2511

[4] Mechanisms of resistance and sensitivity to anti-HER2 therapies in HER2+breast cancer [J].

Gagliato, Debora de Melo ;

Fontes Jardim, Denis Leonardo ;

Pereira Marchesi, Mario Sergio ;

Hortobagyi, Gabriel N. .

ONCOTARGET, 2016, 7 (39) :64431-64446

[5] Neratinib Temsirolimus in HER2-Mutant Lung Cancers: An International, Randomized Phase II Study [J].

Gandhi, Leena ;

Besse, Benjamin ;

Mazieres, Julien ;

Waciar, Saiama ;

Cortot, Alexis ;

Barlesi, Fabrice ;

Quoix, Elisabeth ;

Otterson, Gregory ;

Ettinger, David ;

Horn, Leora ;

Moro-Sibilot, Denis ;

Socinski, Mark ;

Gold, Kathryn ;

Gray, Jhanelle ;

Oton, Ana ;

Heist, Rebecca Suk ;

Costa, Daniel ;

Mcculloch, Leanne ;

Bebchuk, Judith ;

Bryce, Richard ;

Kris, Mark .

JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) :S358-S359

[6] Randomized phase II trial of gemcitabine-cisplatin with or without trastuzumab in HER2-positive non-small-cell lung cancer [J].

Gatzemeier, U ;

Groth, G ;

Butts, C ;

Van Zandwijk, N ;

Shepherd, F ;

Ardizzoni, A ;

Barton, C ;

Ghahramani, P ;

Hirsh, V .

ANNALS OF ONCOLOGY, 2004, 15 (01) :19-27

[7] Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study [J].

Hainsworth, John D. ;

Meric-Bernstam, Funda ;

Swanton, Charles ;

Hurwitz, Herbert ;

Spigel, David R. ;

Sweeney, Christopher ;

Burris, Howard ;

Bose, Ron ;

Yoo, Bongin ;

Stein, Alisha ;

Beattie, Mary ;

Kurzrock, Razelle .

JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06) :536-+

[8] A Phase II Study of Trastuzumab Emtansine in HER2-Positive Non-Small Cell Lung Cancer [J].

Hotta, Katsuyuki ;

Aoe, Keisuke ;

Kozuki, Toshiyuki ;

Ohashi, Kadoaki ;

Ninomiya, Kiichiro ;

Ichihara, Eiki ;

Kubo, Toshio ;

Ninomiya, Takashi ;

Chikamori, Kenichi ;

Harada, Daijiro ;

Nogami, Naoyuki ;

Hirata, Taizo ;

Hinotsu, Shiro ;

Toyooka, Shinichi ;

Kiura, Katsuyuki .

JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (02) :273-279

[9] HER kinase inhibition in patients with HER2-and HER3-mutant cancers [J].

Hyman, David M. ;

Piha-Paul, Sarina A. ;

Won, Helen ;

Rodon, Jordi ;

Saura, Cristina ;

Shapiro, Geoffrey I. ;

Juric, Dejan ;

Quinn, David I. ;

Moreno, Victor ;

Doger, Bernard ;

Mayer, Ingrid A. ;

Boni, Valentina ;

Calvo, Emiliano ;

Loi, Sherene ;

Lockhart, Albert C. ;

Erinjeri, Joseph P. ;

Scaltriti, Maurizio ;

Ulaner, Gary A. ;

Patel, Juber ;

Tang, Jiabin ;

Beer, Hannah ;

Selcuklu, S. Duygu ;

Hanrahan, Aphrothiti J. ;

Bouvier, Nancy ;

Melcer, Myra ;

Murali, Rajmohan ;

Schram, Alison M. ;

Smyth, Lillian M. ;

Jhaveri, Komal ;

Li, Bob T. ;

Drilon, Alexander ;

Harding, James J. ;

Iyer, Gopa ;

Taylor, Barry S. ;

Berger, Michael F. ;

Cutler, Richard E., Jr. ;

Xu, Feng ;

Butturini, Anna ;

Eli, Lisa D. ;

Mann, Grace ;

Farrell, Cynthia ;

Lalani, Alshad S. ;

Bryce, Richard P. ;

Arteaga, Carlos L. ;

Meric-Bernstam, Funda ;

Baselga, Jose ;

Solit, David B. .

NATURE, 2018, 554 (7691) :189-194

[10] Targeting HER2 aberrations as actionable drivers in lung cancers: phase II trial of the pan-HER tyrosine kinase inhibitor dacomitinib in patients with HER2 - mutant or amplified tumors [J].

Kris, M. G. ;

Camidge, D. R. ;

Giaccone, G. ;

Hida, T. ;

Li, B. T. ;

O'Connell, J. ;

Taylor, I. ;

Zhang, H. ;

Arcila, M. E. ;

Goldberg, Z. ;

Jaenne, P. A. .

ANNALS OF ONCOLOGY, 2015, 26 (07) :1421-1427

← 1 2 3 →